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PURPOSE. The cause of noninfectious uveitis (NIU) is poorly understood but is considered to be
mediated by a complex interplay between genetic, environmental, and—relatively
unexplored—epigenetic factors. MicroRNAs (miRNAs) are noncoding small RNAs that are
important epigenetic regulators implicated in pathologic signaling. Therefore, we mapped the
circulating miRNA-ome of NIU patients and studied miRNA perturbations within the broader
context of the immune system.
METHODS. We designed a strategy to robustly identify changes in the miRNA profiles of two
independent cohorts totaling 54 untreated patients with active and eye-restricted disease and
26 age-matched controls. High-resolution miRNA-ome data were obtained by TaqMan
OpenArray technology and subsequent RT-qPCR. Flow cytometry data, and proteomic data
spanning the cellular immune system, were used to map the uveitis-miRNA signature to
changes in the composition of specific leukocyte subsets in blood.
RESULTS. Using stringent selection criteria, we identified and independently validated an
miRNA cluster that is associated with NIU. Pathway enrichment analysis for genes targeted by
this cluster revealed significant enrichment for the PI3K/Akt, MAPK, FOXO, and VEGF
signaling pathways, and photoreceptor development. In addition, unsupervised multidomain
analyses linked the presence of the uveitis-associated miRNA cluster to a different
composition of leukocyte subsets, more specifically, CD16þCD11cþHLA-DR cells.
CONCLUSIONS. Together, this study identified a unique miRNA cluster associated with NIU that
was related to changes in leukocyte subsets demonstrating systemic changes in epigenetic
regulation underlying NIU.
Keywords: microRNA, uveitis, epigenetics, Birdshot, intraocular inflammation
Noninfectious uveitis (NIU) comprises a heterogeneousgroup of recurrent or chronic sight-threatening intraocular
inflammations that eventually lead to permanent visual
impairment or blindness in up to 19% of patients.1–4 Since
NIU affects more than 1 of every 1000 individuals and usually
demands treatment for decades, the clinical and economic
impact of NIU is enormous.5–7
NIU is well acknowledged as an immune-mediated disease.
This is based upon (genetic) association with numerous
immune-related molecules, the frequent occurrence of uveitis
in relation to systemic inflammatory conditions, and the
beneficial response to immunosuppressive therapy.8–12 Despite
our growing understanding that susceptibility to NIU is in part
genetic, and epigenetic modulation contributes to various
ocular conditions, studies investigating the epigenetic land-
scape of uveitis are scarce.13–15
One of the mechanisms through which epigenetic regula-
tion of gene expression takes place is through microRNAs
(miRNAs).16 miRNAs are small RNAs abundantly found in
almost all biological tissues. miRNAs interfere with the
translation of messenger RNA (mRNA) of more than half of
the protein-coding genome and consequently orchestrate
complex biological circuits including immunity.17–20 Although
miRNA binding to mRNA generally has a modest effect on
protein expression, changes in the expression of miRNAs can
have dramatic and widespread impact on cellular signaling.21
As a result, a large number of profiling studies have been
conducted to find changes in the levels of miRNAs that could
potentially be used to diagnose or monitor disease or provide
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novel therapeutic targets for treatment.22,23 But despite their
potential, miRNA profiling studies are particularly prone to low
reproducibility and have hitherto delivered little clinical
utility.24,25 This can in part be attributed to experimental
design (e.g., validation via independent cohorts). In addition,
functional understanding of the implications of changes in
miRNA levels is usually confined to knockdown and/or
overexpression studies of only one or a few targets in single
(nonprimary) cell types.26,27
To overcome the aforementioned limitations, we designed a
strategy to robustly identify differences in the miRNA profile of
the serum of patients with NIU.
MATERIALS AND METHODS
Patients and Patient Material
We collected blood from a total of 54 adult patients with one of
three archetypical types of NIU: HLA-B27–associated acute
anterior uveitis (AU), idiopathic intermediate uveitis (IU), or
Birdshot uveitis (BU). Patients were seen at the outbound
patient clinic of the Department of Ophthalmology of the
University Medical Center Utrecht between July 2014 and
December 2016. Patients were divided between a discovery
cohort (AU: n ¼ 9, IU: n ¼ 9, BU: n ¼ 10) and a replication
cohort (AU: n ¼ 10, IU: n ¼ 6, BU: n ¼ 10). All patients had
active uveitis (new onset or relapse) at the time of sampling.
None of the patients had a related systemic autoinflammatory
or autoimmune disease, nor did they receive systemic
immunomodulatory treatment in the last 3 months, other than
a low dose of oral prednisolone (10 mg, n ¼ 1).
Uveitis was classified and graded in accordance with the
Standardization of Uveitis Nomenclature (SUN) classification.28
For detailed information on the clinical workup see Supple-
mentary Methods. Twenty-six age- and sex-matched anony-
mous blood donors with no history of ocular inflammatory
disease (UMC Utrecht) served as unaffected controls.
This study was conducted in compliance with the
Declaration of Helsinki. Ethical approval was requested and
obtained from the Medical Ethical Research Committee in
Utrecht and all patients signed written informed consent
before participation.
MicroRNA Profiling: OpenArray
Total RNA was extracted from 200 lL serum by using Exiqon’s
miRCURY RNA Isolation Kit for biofluids (Exiqon, Vedbaek,
Denmark), according to the manufacturer’s instructions. RNA
extraction was performed for all serum samples on the same
day and the order of samples randomized according to
previous recommendations.29 Because there are currently no
universally applicable endogenous serum control miRNAs and
to facilitate reproducibility (standardized controls), we used
nonhuman miRNA (ath-MiR-159a) as a spike-in control for
normalization.30 More details on RNA isolation are provided in
the Supplementary Methods.
We screened for 758 miRNAs in the serum of the discovery
cohort by using the TaqMan OpenArray platform (Thermo
Fisher, Waltham, MA, USA) according to the manufacturer’s
instructions (see also Supplementary Methods). The resulting
expression levels, given in cycle threshold (Crt) values of all
miRNAs, were normalized by subtraction of the mean Crt value
of the spike-in, resulting in a deltaCrt (DCrt ¼ Crt mean target 
Crt mean miR-159a). Differences in miRNA expression levels
between patients and controls were assessed by comparing
these DCrt values of patients to healthy controls, using the
comparative threshold cycle method.31 In short, expression
levels are presented as the fold change (FC ¼ 2DDCt, where
DDCrt¼DCrt patientDCrt reference) as compared to the healthy
control that represented the median of the spike-in and was set
to 1(FC). miRNAs were selected for validation if they were well
expressed (mean Crt < 27, amplification score of >1.24), in
>90% of all samples, with FC of ‡2 or <0.5, and a P value of
<0.05.
Validation of miRNAs: TaqMan Single RT-qPCR
We performed TaqMan single quantitative reverse transcrip-
tion–PCR (RT-qPCR) (see also Supplementary Methods) for 10
miRNAs that passed the selection criteria, on the same samples
from the discovery cohort. The Ct values from the TaqMan
assay were compared with the Crt values from the OpenArray
platform. miRNAs were considered technically validated when
Spearman’s q > 0.5 and P < 0.05. All validated miRNAs were
tested in a second, independent replication cohort (n¼ 36) for
biological validation.
Statistical Approaches
The OpenArray output was analyzed by using the Thermo
Fisher Cloud software, which follows an independent samples
t-test to compare DDC(r)t data with a P value threshold below
0.05 (two-tailed). To facilitate discovery of potentially mean-
ingful mediators, we applied correction for multiple testing
only to the combined data set (discoveryþ replication cohort),
which was obtained after a more robust three-staged strategy
of discovery, validation, and replication using independent
technologies and cohorts. In the combined cohorts, nonpara-
metric tests (Mann-Whitney U test, Kruskal-Wallis with post
hoc Dunn’s with adjusted P values, Spearman’s q) were used to
compare groups or test for correlations. Selected individual
miRNAs were subjected to receiver operating characteristic
(ROC) curves using the FC values.
Details on the association between miRNAs (DDCt) and
clinical characteristics are described in Supplementary Meth-
ods. To correct for multiple testing, a P value of <0.0055 (0.05/
9 clinical parameters) was considered significant.
The FC values (or singular value decomposition imputed
values, max 10%) for miRNAs that met the amplification and
expression criteria were subjected to unsupervised hierarchi-
cal clustering (Euclidian distance, Ward’s linkage method).
Clustering was performed with ClustVis or MetaboAnalyst.32,33
Statistical analyses were performed in SPSS version 21.0 (SPSS,
Inc., Chicago, IL, USA), GraphPad Prism (GraphPad, La Jolla,
CA, USA), MetaboAnalyst Server v3.0, and R v3.3.2.
Target Analysis
Predicted and reported mRNA targets of the validated miRNAs
were mapped by using miRGATE34 and MirTargetLink.35
Pathway enrichment analysis was performed for Gene Ontol-
ogy (GO) biological processes,36 Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathways,37 and Pathway Ontology
(PW) pathways38 on all gene targets that were targeted by at
least two miRNAs, using ToppGene Suite (BMI CCHMC,
Cincinnati, OH, USA).39 To visualize shared pathways, unscaled
false discovery rate (FDR)-corrected P values for pathways
related to inflammation and eye biology were outlined in a
heatmap generated by Clustvis software.32
Leukocyte Cell Subset MicroRNA and Proteome
Analyses
Global miRNA expression data for nine primary leukocyte
populations were derived from four noncoding RNA micro-
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array data sets available via the Gene Expression Omnibus (see
Supplementary Methods). Normalized miRNA profiles (n ¼
825) for these leukocyte subsets were subjected to hierarchical
clustering or principle component analysis to interrogate
global miRNA expression profiles (MetaboAnalyst 3.0).33 Mass
spectrometry–based proteomics data for the nine primary
leukocyte subsets (162 samples) were used to obtain the cell-
specific protein expression data.40 For detailed information see
Supplementary Methods.
Flow Cytometry Analysis of Lymphoid and
Myeloid Populations
Peripheral blood mononuclear cells (PBMCs) from 30 patients
and 15 healthy controls were obtained by Ficoll gradient
centrifugation and stored at 808C. Thawed PBMCs were
stained with antibodies listed in Supplementary Table S1,
randomized for measurement by BD LSR Fortessa Cell Analyzer
(BD Bioscience, San Jose, CA, USA). Samples were grouped
according to low miR-233-3p versus high miR-233-3p levels
(cutoff < FC 1.29 ‡ median of unaffected controls; Supple-
mentary Table S2).
To minimize technical variability inherent to manual gating,
we performed unsupervised hierarchical clustering by using
Citrus41 on 50,000 random events from pregated (Supplemen-
tary Fig. S1) viable single cells exported from Flow Jo Software
for each sample with a 1% minimum cluster size to reduce
granularity and arcsin hyperbolic transformation value at 200.
In short, Citrus applies an unsupervised clustering algorithm to
map the hierarchy of phenotypically related cell clusters,
which results in a so-called tree. This is followed by a
supervised classification model to highlight stratifying clusters
for predefined conditions (high versus low miRNA levels). Cells
were clustered by the expression of lineage (CD3/CD56/
CD19), CD14, CD1c, HLA-DR, CD123, CD11c, CD141, and
CD303 proteins. Since we investigated groups with unequal
numbers of samples, we explored the abundance of cell
populations by using the significance analysis of microarrays
(SAM) with significance inferred for false discovery rate < 1%.
RESULTS
High-Throughput miRNA Profiling Reveals 10
Differentially Expressed miRNAs
We devised a three-staged strategy with stringent selection
criteria to identify differently expressed miRNAs in serum of
NIU patients (Supplementary Fig. S2). The demographic data of
the NIU patients and controls from the discovery cohort and
the replication cohort are shown in the Table. First, we
screened for 758 circulating miRNAs in 28 patients and 16
healthy controls (discovery cohort) by using a high-throughput
real-time PCR platform (OpenArray). A total of 102 miRNAs
passed quality control (Supplementary Table S3). We could
distinguish patients from controls from the overall miRNA
profile (Fig. 1), which exhibited mostly increased levels for
most detected miRNAs (Supplementary Fig. S3). To aid in the
elimination of background variation and improve reproducibil-
ity of our findings, we maintained a stringent 2-fold change
cutoff and P < 0.05 for significance. This approach yielded six
miRNAs (miR-140-5p, miR-491-5p, miR-223-3p, miR-223-5p,
miR-193a-5p, and miR-29a-3p) and a small nuclear RNA (U6
snRNA) that were upregulated in one or more patient groups
compared to healthy controls (Supplementary Fig. S3; Supple-
mentary Table S4). Between the uveitis groups, three miRNAs
(miR-127-3p, miR-375, miR-409-3p) were differentially ex-
pressed (Supplementary Fig. S3; Supplementary Table S4),
resulting in a total of 10 miRNAs that were selected for
replication.
High-throughput miRNA profiling technologies are inher-
ently prone to detect certain miRNAs over others.42,43 We
performed several investigations that showed no apparent
detection bias and thus we consider the detected miRNA
profile a genuine representative sample of the blood-borne
miRNA-ome of NIU (see Supplementary Methods; Supplemen-
tary Fig. S4).
Replication of Seven Serum miRNAs in an
Independent Cohort
We next technically validated the miRNAs from the discovery
cohort by using RT-qPCR. The expression levels for 9/10
miRNAs demonstrated strong correlation (q, 0.55–0.97; all P 
0.0001) between these technologies and were thus considered
technically validated (Fig. 2; Supplementary Table S4). Next,
we investigated the levels of these nine miRNAs in an
independent cohort of 26 patients and 10 controls (Table).
Biological replication was achieved for six miRNAs (miR-140-
5p, miR-193a-5p, miR-223-3p, miR-223-5p, miR-29a-3p, and
miR-491-5p) and U6 snRNA in at least one of the uveitis disease
groups versus healthy controls (Fig. 2; Supplementary Table
S4). All were significantly more highly expressed in uveitis
patients than the controls (Fig. 2D).
Since an increase in the levels of the replicated miRNAs was
observed for all uveitis subtypes, we combined the TaqMan RT-
qPCR data from both cohorts to investigate the discriminative
power of the uveitis-associated cluster. The analysis of the area
TABLE. Characteristics of the Discovery and Replication Cohorts Investigated in This Study
AU IU BU HC P Value
Discovery Cohort
N 9 9 10 16 N/A
Male/female 3/6 2/7 4/6 6/10 0.90*
Age, mean 6 SD, y 47.7 6 17.0 39.3 6 14.0 52.9 6 13.2 41.4 6 9.8 0.09**
Disease duration, median (range), y 5.8 (0.1–39.3) 3.7 (0.2–20.0) 1.3 (0.2–15.1) N/A 0.14***
Replication Cohort
N 10 6 10 10 N/A
Male/female 2/8 3/3 6/4 4/6 0.39*
Age, mean 6 SD, y 45.9 6 16.1 31.7 6 10.5 45.8 6 12.2 41.5 6 14.0 0.19**
Disease duration, median (range), y 8.1 (0.2–22.3) 4.9 (0.4–14.1) 0.9 (0.2–33.2) N/A 0.41***
AU, HLA-B27–associated anterior uveitis; HC, healthy control; N/A, not applicable.
* Fisher’s exact test.
** ANOVA.
*** Kruskal-Wallis.
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under the ROC curve revealed that these miRNAs displayed
relatively good specificity and sensitivity (Supplementary Table
S2).
We observed no statistically significant correlations be-
tween the levels of selected miRNAs and age, sex, lymphocyte
and leukocyte count, development of ocular complications, or
need for treatment with systemic medication. Interestingly, we
did find an inverse correlation between disease duration and
the serum levels of U6 snRNA, which was seemingly driven by
AU patients (Supplementary Fig. S5).
Uveitis-Associated miRNA Cluster Targets
Inflammatory and Ocular Biology Pathways
To aid in the understanding of the widespread downstream
effects of the identified miRNAs in NIU, we narrowed down
relevant disease pathways by selecting genes targeted by at
least two of the uveitis-associated miRNAs by using miRTar-
getLink.35 Together, six miRNAs shared 37 gene targets (Fig.
3A). Pathway enrichment analysis (see Materials and Methods)
for these overlapping gene targets revealed significant (FDR-
corrected P < 0.05) enrichment for inflammatory and ocular
biology pathways (Fig. 3B).
The NIU-Specific miRNA Cluster Is Associated With
Altered Frequencies of CD16þ Leukocytes
The expression levels of the seven miRNAs were strongly
correlated with each other and therefore further considered as
a single uveitis-associated miRNA cluster (Fig. 3C; Supplemen-
tary Fig. S6). We hypothesized that the uveitis-associated
miRNA cluster can reflect specific changes in leukocyte
populations.44–47 To investigate this, we first used noncoding
RNA array data (825 overlapping miRNAs) across 113 samples
of nine primary leukocyte populations—covering most cell
populations of the immune system. Consistent with literature,
the derived miRNA-ome was highly cell-type specific (Fig. 4A).
Principle component analysis clearly distinguished a lymphoid
cluster (T cells, B cells, natural killer [NK] cells) and two
myeloid clusters (Fig. 4B). Among the major miRNAs contrib-
uting to the clustering of these populations were miR-223-3p
and miR-29a-3p (Fig. 4B; Supplementary Fig. S7). The
expression of the other uveitis-associated miRNAs also varied
considerably between the populations (Supplementary Fig.
S8). Using correlation, we mapped the uveitis-associated
miRNAs to remote clusters of expression across the leukocyte
populations (Supplementary Fig. S9). To verify whether the
distinguished expression of the miR-29a-3p and miR-223-3p
across the leukocyte subsets reflects meaningful downstream
biological differences, we mined mass spectrometry–based
proteomic data of the investigated cell subsets (n¼162) for the
expression of validated target genes (Supplementary Fig. S10;
Supplementary Table S5). Unsupervised hierarchical clustering
of the miRNA-target proteome of miR-29a-3p and miR-223-3p
clearly discerned the myeloid and lymphoid cell subsets (Fig.
4C).
Finally, we wished to explore whether the miRNA cluster
tagged changes in specific leukocyte subsets in uveitis patients.
FIGURE 1. Unsupervised hierarchical clustering of the serum miRNA-ome of the discovery cohort. Heatmap of unsupervised hierarchical clustering
based on 102 detected miRNAs that met quality control thresholds from the discovery cohort (screening study). Depicted are the transformed FC
values (see Materials and Methods) from patients with HLA-B27–associated uveitis (AU), IU, BU, and healthy controls (HCs). Unit variance scaling is
applied to rows. Heatmap colors represent the fold changes in a color-coded way: blue (low) to red (high). Clustering was performed with ClustVis
using correlation distance and Ward linkage and is depicted as dendrograms for columns and rows.
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To this aim, we exploited available flow cytometry data from
30 NIU patients and 15 controls from this study (see
Supplementary Methods; Supplementary Table S2). Unbiased
computational mining of the flow cytometry data by Citrus
identified two cell clusters that displayed significantly changed
cell abundance according to the expression of the miRNA
signature. These included a cluster of lymphocytes (cluster A;
Figs. 4D, 4E, and Supplementary Fig. S11) and a cluster of
populations characterized by high CD16 expression, dim
expression of lineage marker (lindim) and CD11c, and low
levels of HLA-DR and the monocyte marker CD14 (cluster B1-3,
Supplementary Fig. S11), reminiscent of CD16þ CD56dim NK
cells.48 This CD16þ cluster also contained populations with
low but distinguished expression of CD141 and CD303, most
likely residual granulocyte populations (cluster B2 and B3; Figs.
4D, 4E).49,50 These observations link a disease-associated
circulating miRNA cluster with marked changes in the
leukocyte repertoire in the blood of patients with NIU.
DISCUSSION
Using a high dimensional and multilevel approach we
identified and independently validated the presence of a
FIGURE 2. Discovery, validation, and replication of seven miRNAs increased in serum of patients with noninfectious uveitis. From left to right: (A)
Results from OpenArray in discovery cohort (n¼ 44). On the y-axis are the relative expression levels (i.e., the transformed FC values [see Materials
and Methods]) shown for the patients as compared to the mean expression of healthy controls. P values are from independent t-test. (B) Correlation
between expression levels for selected miRNAs obtained by OpenArray and TaqMan single RT-qPCR assay. Spearman’s q is used to test for
correlation. (C) Results from TaqMan single RT-qPCR assay in the replication cohort (n¼36). On the y-axis are the relative expression levels (i.e., the
transformed FC values [see Materials and Methods]) shown for the patients as compared to the mean expression of healthy controls. P values are
from independent samples t-test. (D) Results from TaqMan single RT-qPCR assay of both cohorts combined (n¼80) and stratified for uveitis patients
and healthy controls. P values are from Mann-Whitney U test (uveitis versus control). AU, HLA-B27–associated anterior uveitis; HC, healthy control.
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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uveitis-specific miRNA cluster. This uveitis cluster comprised
six miRNAs and a small nuclear RNA that suggest the
involvement of several inflammatory signaling cascades
(PI3K/Akt, MAPK, FOXO, and VEGF signaling) involved in
several eye diseases. In addition, our work showed improved
power to validate (70% of selected miRNAs were replicated) as
well as to understand the potential role of circulating miRNAs
in pathologic conditions without the necessity to have large
cohorts.
NIU denotes a collective of clinically heterogeneous
intraocular inflammatory diseases that share immune charac-
teristics with—and commonly form an underappreciated
feature of—systemic (auto)inflammatory conditions.10,51–53
This led us to deliberately study two cohorts (discovery and
replication cohort) of treatment-free patients with eye-restrict-
ed and active disease. This allowed us to better address the
impact of intraocular inflammation on miRNAs in the
circulation. To the best of our knowledge, this resulted in the
first miRNA investigation of NIU patients without underlying
(or potentially confounding) systemic disease.54–56
The main aim of the study was to explore the circulating
miRNA profile of NIU to better understand its enigmatic
etiology and lay the groundwork for emerging noncoding
RNA–based therapeutics to reverse NIU.57 Yet, a major obstacle
for bringing small RNAs into consideration for therapeutic
targeting is the notoriously low concordance and reproduc-
ibility between available technologies for detecting differential
expression, which consequently results in conflicting reports
on candidate identification. Although recommendations for
quality control58 have improved reproducibility, we also
invested additional efforts in assembling an independent
replication cohort to be able to identify a robust set of
uveitis-associated miRNAs.
The quest for understanding the downstream effects of
serum miRNA perturbations is a highly ambiguous one.
Individual miRNAs regulate numerous genes, while a single
gene can be regulated by a panel of miRNAs.17,59 Yet, most
biological processes are tuned by the concerted action of
multiple miRNAs targeting the same pathways.18,19,60 Given
the close correlation of miRNA levels, as well as overlapping
predicted and experimentally validated pathways, it is tempt-
ing to speculate that the identified miRNA signature acts as a
pathologic ensemble driving—or responding to—ocular in-
flammation. Functional experiments with appropriate multi-
miRNA knockout and conditional (over)expression models will
be necessary to pinpoint the functional consequences of our
observations.
Several recent key studies highlight the importance of our
observations. miR-223-3p is upregulated in animal models of
uveitis and is able to drive inflammation via T cells and myeloid
dendritic cells, two cell types that are implicated in the biology
of uveitis.10,61–65 Myeloid-derived mir-223 is critical to innate
immunity during gut inflammation, and skewed serum levels of
this miRNA may hint toward a dysbiotic microbiome.66–68 This
is particularly interesting, since commensal microbiota can
trigger autoimmune uveitis in mice.69 Consequently, miR-223-
FIGURE 2. Continued
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3p has been suggested as a good candidate for miRNA targeting
in the treatment of inflammatory diseases such as NIU.70
We explored if the levels of the uveitis-associated signature
were correlated with changes in specific blood cell popula-
tions of these same patients. We focused on leukocytes
because previous studies have highlighted a predominant
function of leukocytes in uveitis.10 We realize that the flow
cytometry panels used here may lack the resolution needed for
an in-depth analysis of all leukocyte populations in blood
(outside the scope of this study), yet we were able to highlight
several interesting changes; we identified a decreased frequen-
cy of a cell population distinguished by high CD16 expression.
As based on other cell surface makers (CD11cþHLA-
DRCD14lindim), this cluster most likely represents the
FIGURE 3. miRNA-target analysis of the validated serum microRNAs in noninfectious uveitis. (A) miRNA-target network of established overlapping
mRNA targets of the uveitis-associated miRNAs. miRNAs are depicted in brown boxes and the mRNA targets are depicted in blue (targeted by two
miRNAs) or orange (targeted by three miRNAs) boxes. Lines indicate level of evidence: strong (green), weak (blue), or predicted (yellow). Figure
generated with MirTargetLink. (B) Heatmap of unscaled FDR-corrected P values for miRNA-target pathways related to inflammation and eye biology.
Pathway analysis (ToppGene suite39) was performed on mRNA targets that were shared between at least two miRNAs. Clustering was performed by
using Euclidean distance and Ward linkage. (C) Heatmap of unsupervised hierarchical clustering of the correlation of expression (TaqMan RT-qPCR
for the discovery and replication cohorts combined) for validated serum cluster. Heatmap colors represent Spearman’s q (calculated on ddCT). ERK,
extracellular regulated kinase; FoxO, Forkhead box O; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; ROS, reactive
oxygen species; VEGF, vascular endothelial growth factor.
Discovery of a Uveitis Associated MicroRNA Cluster IOVS j February 2018 j Vol. 59 j No. 2 j 884
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/936739/ on 02/17/2018
cytotoxic CD16þCD56dim NK cells, a cell type that plays a
critical role in the first line of defense against infected,
cancerous, and autoreactive cells. Also, this is the major NK
subset in blood that typically expresses killer immunoglobulin-
like receptors, a receptor that is implicated in the biology of
NIU.48,71
It is tempting to speculate that the increased frequency of
the lymphocyte cluster represents CD4þ T cells. We observed
FIGURE 4. Meta-analysis of the leukocyte miRNA-ome links the uveitis-associated cluster to leukocyte composition in blood. (A) Meta-analysis of the
cellular miRNA-ome (n¼825) of nine primary leukocyte populations (n¼113). Indicated is the average relative cellular miRNA expression for each
investigated cell subset. Ward’s method of hierarchical clustering of miRNA data was performed with Pearson correlation distance. (B) Principle
component analysis (PCA) of the cellular miRNA-ome of the leukocyte subsets. Three populations are clearly distinguishable by the second and third
principal components. Loading plot of PCA shows that miR-29a-3p and miR-223-3p (dark red) are among the top miRNAs (>1.5 loading score, light
blue) that contribute to these clusters. The relative position of the other uveitis-associated miRNAs is indicated. (C) Unsupervised hierarchical
clustering of proteomic data of validated target genes (n¼ 74; Supplementary Fig. S9, Supplementary Table S4) for miR-29a-3p and miR-223-3p in
nine leukocyte cell subsets (see Materials and Methods) distinguishes lymphocyte and myeloid populations. (D) Citrus tree of identified common
cell populations (>1% of sample) in blood that distinguishes individuals with relatively high levels of the uveitis-associated miRNA cluster from
individuals with relatively lower levels in serum. Contours indicate clusters (A and B) with a significantly different abundance in individuals with
relatively higher miRNA levels (SAM, by FDR of 1%). Expression of CD16 and lineage (CD3/CD19/CD56) marker is indicated in color scale. High-
dimensional phenotype for each cluster is outlined in Supplementary Figure S10. (E) Histogram plots of the relative expression of each cell surface
marker by the identified clusters (red) compared to the overall expression of all other clusters (blue). The relative abundance of the identified
clusters in individuals with high/low levels of the uveitis-associated miRNA cluster is indicated.
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that the uveitis-associated miR-140-5p and mir-29a-3p are
typically more highly expressed in lymphocyte populations,
including CD4þ T cells. miR-140-5p, which had the highest
discriminative power between uveitis patients and controls, is
aberrantly expressed and implicated in pathogenic T-cell
function in multiple sclerosis,72,73 a disease linked to IU.74–76
It is important to emphasize, however, that the functions of
miR-140-5p (and miR-29a-3p) most likely expand beyond T-cell
function. For example, we also noted associated pathways
relevant for ocular biology, including VEGF signaling,77–79
photoreceptor development, and retina homeostasis.80,81
These ocular biology pathways may attempt to control damage
to ocular tissues.
U6 snRNA is a small nuclear RNA (snRNA) that is normally
localized in the nucleus, but blood microvesicles or exo-
somes—which vastly increase in number in the circulation
during inflammation82—are also particularly enriched for U6
nuclear RNA.83,84 Curiously, U6 snRNA is widely used for
normalization of miRNA expression studies,85,86 while we here
showed that the levels of this miRNA are robustly upregulated
in the serum of uveitis patients. This is also increasingly
reported for other conditions.87–90
Our results have to be interpreted with the following study
limitations in mind. First, although we believe that our
stringent selection criteria contributed to the robust identifi-
cation and replication of uveitis-associated miRNAs, it conse-
quently also limited sample size and power to detect more
subtle differences. It seems reasonable to speculate that this
may have prevented the detection of a relation between the
miRNA levels and heterogeneous clinical end-points, and
hampered the validation of differences between uveitis
subtypes. Overall, we would like to emphasize that the study
of miRNAs in serum is by no means exhaustive, and
recapitulate that the identified miRNAs most likely function
in clusters of functionally related mediators that orchestrate
molecular route function into complex behavior of the
immune system in uveitis. As such, the here identified miRNA
signature serves as an important starting point to further
functionally dissect the epigenetic regulation by these miRNAs
and their interaction within the cellular immune system of
patients with NIU.
In conclusion, our data demonstrate systemic changes in
epigenetic regulation that link serum miRNA levels to changes
in leukocyte populations underlying inflammatory eye disease.
Acknowledgments
The authors thank Eleni Chouri and Jorre Mertens for analytical
support and useful discussions.
Supported by unrestricted grants from Dr. F.P. Fischer-Stichting and
LSBS. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Disclosure: F.H. Verhagen, None; C.P.J. Bekker, None; M.
Rossato, None; S. Hiddingh, None; L. de Vries, None; A.
Devaprasad, None; A. Pandit, None; J. Ossewaarde-van Norel,
None; N. ten Dam, None; M.C.A. Moret-Pot, None; S.M. Imhof,
None; J.H. de Boer, None; T.R.D.J. Radstake, None; J.J.W.
Kuiper, None
References
1. Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray
PI. Degree, duration, and causes of visual loss in uveitis. Br J
Ophthalmol. 2004;88:1159–1162.
2. Dick AD, Tundia N, Sorg R, et al. Risk of ocular complications
in patients with noninfectious intermediate uveitis, posterior
uveitis, or panuveitis. Ophthalmology. 2016;123:655–662.
3. Verhagen FH, Brouwer AH, Kuiper JJW, Ossewaarde-van
Norel J, ten Dam-van Loon NH, de Boer JH. Potential
predictors of poor visual outcome in human leukocyte
antigen-B27–associated uveitis. Am J Ophthalmol. 2016;165:
179–187.
4. Tomkins-Netzer O, Talat L, Bar A, et al. Long-term clinical
outcome and causes of vision loss in patients with uveitis.
Ophthalmology. 2014;121:2387–2392.
5. Thorne JE, Suhler E, Skup M, et al. Prevalence of noninfec-
tious uveitis in the United States. JAMA Ophthalmol. 2016;
134:1237–1245.
6. Mun˜oz-Ferna´ndez S, Mart´ın-Mola E. Uveitis. Best Pract Res
Clin Rheumatol. 2006;20:487–505.
7. De Smet MD, Taylor SRJ, Bodaghi B, et al. Understanding
uveitis: the impact of research on visual outcomes. Prog Retin
Eye Res. 2011;30:452–470.
8. Perez VL, Caspi RR. Immune mechanisms in inflammatory and
degenerative eye disease. Trends Immunol. 2015;36:354–
363.
9. Yang M-M, Lai TYY, Luk FOJ, Pang C-P. The roles of genetic
factors in uveitis and their clinical significance. Retina. 2014;
34:1–11.
10. Lee RW, Nicholson LB, Sen HN, et al. Autoimmune and
autoinflammatory mechanisms in uveitis. Semin Immunopa-
thol. 2014;36:581–594.
11. Hou S, Kijlstra A, Yang P. Molecular genetic advances in
uveitis. Prog Mol Biol Transl Sci. 2015;134:283–298.
12. Kuiper J, Rothova A, de Boer J, Radstake T. The immuno-
pathogenesis of birdshot chorioretinopathy: a bird of many
feathers. Prog Retin Eye Res. 2015;44:99–110.
13. Liu MM, Chan C-C, Tuo J. Epigenetics in ocular diseases. Curr
Genomics. 2013;14:166–172.
14. Berber P, Grassmann F, Kiel C, Weber BHF. An eye on age-
related macular degeneration: the role of microRNAs in
disease pathology. Mol Diagn Ther. 2017;21:31–43.
15. Pradhan P, Upadhyay N, Tiwari A, Singh LP. Genetic and
epigenetic modifications in the pathogenesis of diabetic
retinopathy: a molecular link to regulate gene expression.
New Front Ophthalmol. 2016;2:192–204.
16. Dawson MA, Kouzarides T. Cancer epigenetics: from mech-
anism to therapy. Cell. 2012;150:12–27.
17. Iwakawa HO, Tomari Y. The functions of microRNAs: mRNA
decay and translational repression. Trends Cell Biol. 2015;25:
651–665.
18. Londin E, Loher P, Telonis AG, et al. Analysis of 13 cell types
reveals evidence for the expression of numerous novel
primate- and tissue-specific microRNAs. Proc Natl Acad Sci
U S A. 2015;112:E1106–E1115.
19. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA
annotation and deep-sequencing data. Nucleic Acids Res.
2011;39:D152–D157.
20. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often
flanked by adenosines, indicates that thousands of human
genes are microRNA targets. Cell. 2005;120:15–20.
21. Baek D, Ville´n J, Shin C, Camargo FD, Gygi SP, Bartel DP. The
impact of microRNAs on protein output. Nature. 2008;455:
64–71.
22. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical
relevance of circulating cell-free microRNAs in cancer. Nat
Rev Clin Oncol. 2014;11:145–156.
23. Zeng L, Cui J, Wu H, Lu Q. The emerging role of circulating
microRNAs as biomarkers in autoimmune diseases. Autoim-
munity. 2014;47:419–429.
24. Moldovan L, Batte KE, Trgovcich J, Wisler J, Marsh CB, Piper
M. Methodological challenges in utilizing miRNAs as circulat-
ing biomarkers. J Cell Mol Med. 2014;18:371–390.
Discovery of a Uveitis Associated MicroRNA Cluster IOVS j February 2018 j Vol. 59 j No. 2 j 886
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/936739/ on 02/17/2018
25. Rice J, Roberts H, Burton J, et al. Assay reproducibility in
clinical studies of plasma miRNA. PLoS One. 2015;10:1–23.
26. Yin Z, Cui Z, Ren Y, Xia L, Li H, Zhou B. MiR-146a
polymorphism correlates with lung cancer risk in Chinese
nonsmoking females. Oncotarget. 2017;8:2275–2283.
27. Wang S, Liu JC, Ju Y, et al. microRNA-143/145 loss induces Ras
signaling to promote aggressive Pten-deficient basal-like
breast cancer. JCI Insight. 2017;2:e93313.
28. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of
uveitis nomenclature for reporting clinical data: results of the
First International Workshop. Am J Ophthalmol. 2005;140:
509–516.
29. Schwochow D, Serieys LEK, Wayne RK, Thalmann O. Efficient
recovery of whole blood RNAa comparison of commercial
RNA extraction protocols for high-throughput applications in
wildlife species. BMC Biotechnol. 2012;12:33.
30. Schwarzenbach H, Da Silva AM, Calin G, Pantel K. Data
normalization strategies for microRNA quantification. Clin
Chem. 2015;61:1333–1342.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression
data using real-time quantitative PCR and the 2(-Delta Delta
C(T)) method. Methods. 2001;25:402–408.
32. Metsalu T, Vilo J. ClustVis: a web tool for visualizing clustering
of multivariate data using Principal Component Analysis and
heatmap. Nucleic Acids Res. 2015;43:W566–W570.
33. Xia J, Wishart DS. Using MetaboAnalyst 3.0 for comprehensive
metabolomics data analysis. In: Current Protocols in Bio-
informatics. Vol 55. Hoboken, NJ: John Wiley & Sons, Inc.;
2016:14.10.1–14.10.91.
34. Andre´s-Leo´n E, Gonza´lez Pen˜a D, Go´mez-Lo´pez G, Pisano DG.
miRGate: a curated database of human, mouse and rat miRNA-
mRNA targets. Database (Oxford). 2015; 2015:bav035.
35. Hamberg M, Backes C, Fehlmann T, et al. MiRTargetLink—
miRNAs, genes and interaction networks. Int J Mol Sci. 2016;
17:564.
36. Ashburner M, Ball CA, Blake JA, et al; for the Gene Ontology
Consortium. Gene ontology: tool for the unification of
biology. Nat Genet. 2000;25:25–29.
37. Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and
genomes. Nucleic Acids Res. 2000;28:27–30.
38. Petri V, Jayaraman P, Tutaj M, et al. The pathway ontology -
updates and applications. J Biomed Semantics. 2014;5:7.
39. Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for
gene list enrichment analysis and candidate gene prioritiza-
tion. Nucleic Acids Res. 2009;37(suppl 2):305–311.
40. Rieckmann JC, Geiger R, Hornburg D, et al. Social network
architecture of human immune cells unveiled by quantitative
proteomics. Nat Immunol. 2017;18:583–593.
41. Bruggner RV, Bodenmiller B, Dill DL, Tibshirani RJ, Nolan GP.
Automated identification of stratifying signatures in cellular
subpopulations. Proc Natl Acad Sci U S A. 2014;111:E2770–
E2777.
42. Backes C, Sedaghat-Hamedani F, Frese K, et al. Bias in high-
throughput analysis of miRNAs and implications for biomark-
er studies. Anal Chem. 2016;88:2088–2095.
43. Mitiushkina NV, Iyevleva AG, Kuligina ES, Togo AV, Miki Y,
Imyanitov EN. Biased detection of guanine-rich microRNAs by
array profiling: systematic error or biological phenomenon? J
Comput Sci. 2014;5:351–356.
44. Kuiper JJW, Rothova A, Schellekens PAW, Ossewaarde-van
Norel A, Bloem AC, Mutis T. Detection of choroid- and retina-
antigen reactive CD8þ and CD4þ T lymphocytes in the
vitreous fluid of patients with birdshot chorioretinopathy.
Hum Immunol. 2014;75:570–577.
45. Chen P, Denniston AK, Hirani S, Hannes S, Nussenblatt RB.
Role of dendritic cell subsets in immunity and their
contribution to noninfectious uveitis. Surv Ophthalmol.
2015;60:242–249.
46. Smith JR, Stempel AJ, Bharadwaj A, Appukuttan B. Involve-
ment of B cells in non-infectious uveitis. Clin Transl
Immunol. 2016;5:e63.
47. Lipski DA, Dewispelaere R, Foucart V, et al. MHC class II
expression and potential antigen-presenting cells in the retina
during experimental autoimmune uveitis. J Neuroinflamma-
tion. 2017;14:136.
48. Moretta L. Dissecting CD56dim human NK cells. Blood. 2010;
116:3689–3691.
49. Carmona-Rivera C, Kaplan MJ. Low-density granulocytes: a
distinct class of neutrophils in systemic autoimmunity. Semin
Immunopathol. 2013;35:455–463.
50. Geijtenbeek TBH, Gringhuis SI. Signalling through C-type
lectin receptors: shaping immune responses. Nat Rev
Immunol. 2009;9:465–479.
51. Caspi RR. A look at autoimmunity and inflammation in the
eye. J Clin Invest. 2010;120:3073–3083.
52. Wakefield D, Yates W, Amjadi S, McCluskey P. HLA-B27
anterior uveitis: immunology and immunopathology. Ocul
Immunol Inflamm. 2016;24:450–459.
53. Mesquida M, Molins B, Llorenc¸ V, de la Maza MS, Ada´n A.
Targeting interleukin-6 in autoimmune uveitis. Autoimmun
Rev. 2017;16:1079–1089.
54. Zhou Q, Xiao X, Wang C, et al. Decreased microRNA-155
expression in ocular Behcet’s disease but not in Vogt
Koyanagi Harada syndrome. Invest Ophthalmol Vis Sci.
2012;53:5665–5674.
55. Qi J, Hou S, Zhang Q, et al. A functional variant of pre-miRNA-
196a2 confers risk for Behcet’s disease but not for Vogt–
Koyanagi–Harada syndrome or AAU in ankylosing spondylitis.
Hum Genet. 2013;132:1395–1404.
56. Yang L, Du L, Yue Y, et al. miRNA copy number variants
confer susceptibility to acute anterior uveitis with or without
ankylosing spondylitis. Invest Ophthalmol Vis Sci. 2017;58:
1991–2001.
57. Adams BD, Parsons C, Walker L, Zhang WC, Slack FJ. Targeting
noncoding RNAs in disease. J Clin Invest. 2017;127:761–771.
58. Mestdagh P, Hartmann N, Baeriswyl L, et al. Evaluation of
quantitative miRNA expression platforms in the microRNA
quality control (miRQC) study. Nat Methods. 2014;11:809–815.
59. Pasquinelli AE. MicroRNAs and their targets: recognition,
regulation and an emerging reciprocal relationship. Nat Rev
Genet. 2012;13:271–282.
60. Tsang JS, Ebert MS, van Oudenaarden A. Genome-wide
dissection of microRNA functions and cotargeting networks
using gene set signatures. Mol Cell. 2010;38:140–153.
61. Hsu Y-R, Chang S-W, Lin Y-C, Yang C-H. Expression of
MicroRNAs in the eyes of Lewis rats with experimental
autoimmune anterior uveitis. Mediators Inflamm. 2015;
2015:1–11.
62. Guo D, Li J, Liu Z, Tang K, Song H, Bi H. Characterization of
microRNA expression profiling in peripheral blood lympho-
cytes in rats with experimental autoimmune uveitis. Inflamm
Res. 2015;64:683–696.
63. Ifergan I, Chen S, Zhang B, Miller SD. Cutting edge: micro-
RNA-223 regulates myeloid dendritic cell–driven Th17 re-
sponses in experimental autoimmune encephalomyelitis. J
Immunol. 2016;196:1455–1459.
64. Chen P, Urzua CA, Knickelbein JE, et al. Elevated CD1c þ
myeloid dendritic cell proportions associate with clinical
activity and predict disease reactivation in noninfectious
uveitis. Invest Opthalmol Vis Sci. 2016;57:1765–1772.
65. Chen P, Tucker W, Hannes S, et al. Levels of blood CD1cþ
mDC1 and CD1chi mDC1 subpopulation reflect disease
Discovery of a Uveitis Associated MicroRNA Cluster IOVS j February 2018 j Vol. 59 j No. 2 j 887
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/936739/ on 02/17/2018
activity in noninfectious uveitis. Invest Ophthalmol Vis Sci.
2015;56:346–351.
66. Zhou H, Xiao J, Wu N, et al. MicroRNA-223 regulates the
differentiation and function of intestinal dendritic cells and
macrophages by targeting C/EBPb. Cell Rep. 2015;13:1149–
1160.
67. Neudecker V, Haneklaus M, Jensen O, et al. Myeloid-derived
miR-223 regulates intestinal inflammation via repression of
the NLRP3 inflammasome. J Exp Med. 2017;214:1737–1752.
68. Wang H, Chao K, Ng SC, et al. Pro-inflammatory miR-223
mediates the cross-talk between the IL23 pathway and the
intestinal barrier in inflammatory bowel disease. Genome
Biol. 2016;17:58.
69. Horai R, Sen HN, Caspi RR. Commensal microbiota as a
potential trigger of autoimmune uveitis. Expert Rev Clin
Immunol. 2017;13:291–293.
70. Aziz F. The emerging role of miR-223 as novel potential
diagnostic and therapeutic target for inflammatory disorders.
Cell Immunol. 2016;303:1–6.
71. Levinson RD. Killer immunoglobulin-like receptor genes in
uveitis. Ocul Immunol Inflamm. 2011;19:192–201.
72. Guan H, Singh UP, Rao R, et al. Inverse correlation of
expression of microRNA-140-5p with progression of multiple
sclerosis and differentiation of encephalitogenic T helper type
1 cells. Immunology. 2016;147:488–498.
73. Lewkowicz P, Cwiklin´ska H, Mycko MP, et al. Dysregulated
RNA-induced silencing complex (RISC) assembly within CNS
corresponds with abnormal miRNA expression during auto-
immune demyelination. J Neurosci. 2015;35:7521–7537.
74. Ness T, Boehringer D, Heinzelmann S. Intermediate uveitis:
pattern of etiology, complications, treatment and outcome in
a tertiary academic center. Orphanet J Rare Dis. 2017;12:81.
75. Olsen TG, Frederiksen J. The association between multiple
sclerosis and uveitis. Surv Ophthalmol. 2017;62:89–95.
76. Gordon LK, Goldstein DA. Gender and uveitis in patients with
multiple sclerosis. J Ophthalmol. 2014;2014:1–5.
77. Sun J, Tao S, Liu L, Guo D, Xia Z, Huang M. MIR-140-5p
regulates angiogenesis following ischemic stroke by targeting
VEGFA. Mol Med Rep. 2016;13:4499–4505.
78. Hu Y, Li Y, Wu C, et al. MicroRNA-140-5p inhibits cell
proliferation and invasion by regulating VEGFA/MMP2 signal-
ing in glioma. Tumour Biol. 2017;39:1–12.
79. Zhang W, Zou C, Pan L, et al. MicroRNA-140-5p inhibits the
progression of colorectal cancer by targeting VEGFA. Cell
Physiol Biochem. 2015;37:1123–1133.
80. Xu S, Witmer PD, Lumayag S, Kovacs B, Valle D. MicroRNA
(miRNA) transcriptome of mouse retina and identification of a
sensory organ-specific miRNA cluster. J Biol Chem. 2007;282:
25053–25066.
81. Ertekin S, Yıldırım O, Dinc¸ E, Ayaz L, Fidancı SB, Tamer L.
Evaluation of circulating miRNAs in wet age-related macular
degeneration. Mol Vis. 2014;20:1057–1066.
82. Momen-Heravi F, Saha B, Kodys K, Catalano D, Satishchandran
A, Szabo G. Increased number of circulating exosomes and
their microRNA cargos are potential novel biomarkers in
alcoholic hepatitis. J Transl Med. 2015;13:261.
83. Savelyeva AV, Kuligina EV, Bariakin DN, et al. Variety of RNAs
in peripheral blood cells, plasma, and plasma fractions.
Biomed Res Int. 2017;2017:1–10.
84. Mroczek S, Dziembowski A. U6 RNA biogenesis and disease
association. Wiley Interdiscip Rev RNA. 2013;4:581–592.
85. Crossland RE, Norden J, Bibby LA, Davis J, Dickinson AM.
Evaluation of optimal extracellular vesicle small RNA isolation
and qRT-PCR normalisation for serum and urine. J Immunol
Methods. 2016;429:39–49.
86. Zheng G, Wang H, Zhang X, et al. Identification and
validation of reference genes for qPCR detection of serum
microRNAs in colorectal adenocarcinoma patients. PLoS One.
2013;8:1–10.
87. Lim QE, Zhou L, Ho YK, Wan G, Too HP. snoU6 and 5S RNAs
are not reliable miRNA reference genes in neuronal differen-
tiation. Neuroscience. 2011;199:32–43.
88. Tang G, Shen X, Lv K, Wu Y, Bi J, Shen Q. Different
normalization strategies might cause inconsistent variation in
circulating microRNAs in patients with hepatocellular carci-
noma. Med Sci Monit. 2015;21:617–624.
89. Xiang M, Zeng Y, Yang R, et al. U6 is not a suitable
endogenous control for the quantification of circulating
microRNAs. Biochem Biophys Res Commun. 2014;454:
210–214.
90. Benz F, Roderburg C, Vargas Cardenas D, et al. U6 is unsuitable
for normalization of serum miRNA levels in patients with sepsis
or liver fibrosis. Exp Mol Med. 2013;45:e42.
Discovery of a Uveitis Associated MicroRNA Cluster IOVS j February 2018 j Vol. 59 j No. 2 j 888
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/936739/ on 02/17/2018
